---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-034917"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2023-10-23T23:59:59+00:00"
generated_at: "2026-06-09T17:03:27.890434+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcutis Biotherapeutics prices public offering of 32.5M shares and pre-funded warrants for ~$93.5M net

## Summary
- Offering: 32.5M common shares at $2.50 each plus pre-funded warrants for 7.5M shares at $2.4999 each.
- Net proceeds expected ~$93.5M after discounts and expenses; closing expected October 24, 2023.
- Underwriters granted 30-day option to purchase up to 6M additional common shares.
- Pre-funded warrants have $0.0001 exercise price and include 9.99% beneficial ownership limitation (adjustable to 19.99%).

## SEC filing metadata
- accession: 0001628280-23-034917
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2023-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000162828023034917/0001628280-23-034917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000162828023034917/arqt-20231019.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-034917
- JSON: https://secwatch.observer/filing/0001628280-23-034917.json
- Plain text: https://secwatch.observer/filing/0001628280-23-034917.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.